We are 4,4-Difluoro-N-[(1S)-3-hydroxy-1-phenylpropyl]cyclohexanecarboxamide CAS:376348-77-5 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Product Name: 4,4-Difluoro-N-[(1S)-3-hydroxy-1-phenylpropyl]cyclohexanecarboxamide
Synonym: (S)-4,4-difluoro-N-(3-hydroxy-1-phenylpropyl)cyclohexanecarboxamide; Intermediate of Maraviroc
Cas No.: 376348-77-5
EINECS No.: 638-778-4
HS Code: 2903890090
UN No.: N.A
Hazard class: Non-dangerous goods
|Items of Analysis||Standard of Analysis||Test Results|
|Appearance||White or similar white powder||Conforms|
|Loss on drying||≤0.5%||0.12%|
|Residue on Ignition||≤0.15%||0.13%|
|Conclusion||Conforms to Factory Standard|
Intermediate of Maraviroc.
25 kg/barrel, can also be packaged according to customer requirements.
Store in a cool, ventilated warehouse.
Keep away from fire and heat.
The temperature should not exceed 37 °C.
Related News: Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.6-hydroxy-7-methoxy-1H-quinazolin-4-one CAS:179688-52-9 Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.877384-16-2 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank.